BioSpace News Archive

Business

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Takeda announced financial results for the third quarter of fiscal year 2022.

February 2, 2023

·

17 min read

Business

Vitrolife AB Fourth quarter and full year report 2022: Strong profitable growth

Bronwyn Brophy is appointed as new CEO of Vitrolife AB (publ). She will join the company at the latest of 1 August 2023.

February 2, 2023

·

3 min read

Drug Development

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma

Anaveon, a clinical stage, immuno-oncology company, announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study assessing the efficacy and safety of ANV419 for the treatment of advanced melanoma.

February 2, 2023

·

2 min read

Business

Spago Nanomedical Year-end Report January-December, 2022

Spago Nanomedical initiated a Phase IIa clinical trial with SpagoPix in patients with suspected endometriosis, a chronic, debilitating condition that affects up to 10% of women of reproductive age.

February 2, 2023

·

5 min read

Lone Star Bio

Milestone in development of state-of-the-art compact plasma accelerators as TAU Systems signs a suite of key agreements with The University of Texas at Austin

TAU Systems announced the signing of a suite of crucial agreements with The University of Texas at Austin to focus on the fundamental elements of laser-plasma interactions, advancing the science and technology of compact accelerator systems and advanced light sources, with the goal of making these tools widely available to a broad range of end-users and industry.

February 2, 2023

·

3 min read

Sequana Medical Notice of 2022 Full Year Results and Business Update

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its full year results ended 31 December 2022 on Thursday, 9 February 2023.

February 2, 2023

·

3 min read

Drug Development

SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan

SONIRE Therapeutics Inc., based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE’s next-generation High-Intensity Focused Ultrasound therapy system.

February 2, 2023

·

2 min read

Servier full year 2021/22 results confirm the transformation trajectory of the Group

Servier, an independent global pharmaceutical group, has announced its financial results for the 2021/22 financial year and highlighted the major steps of its ongoing transformation.

February 2, 2023

·

2 min read

Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting

Sensorion is pleased to announce its participation, in-person, in the Association for Research in Otolaryngology 46th Annual MidWinter Meeting, taking place on February 11-15, 2023, in Orlando, Florida, United States.

February 2, 2023

·

4 min read

Drug Development

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, released the final results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

February 2, 2023

·

8 min read